Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | MicrobiomeTrials← Back to trialsNCT05155033
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-08-18Est. Completion: 2031-09-01
Enrollment target: 78 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients …
Birmingham, United StatesEst. completion Dec 31, 2026
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
Recurrent Melanoma
Unresectable Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trameti…
Birmingham, United StatesEst. completion Sep 30, 2023
MelanomaDysplastic Nevus Syndrome
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of s…
Bethesda, United States